Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated:  12/7/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated: 12/7/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated:  12/7/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated: 12/7/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated:  12/7/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated: 12/7/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated:  12/7/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
Status: Enrolling
Updated: 12/7/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/7/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/7/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Azacitidine and CAPOX in Metastatic Colorectal Cancer
Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands
Status: Enrolling
Updated:  12/8/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Azacitidine and CAPOX in Metastatic Colorectal Cancer
Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands
Status: Enrolling
Updated: 12/8/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation
Status: Enrolling
Updated:  12/13/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation
Status: Enrolling
Updated: 12/13/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of KCC Peptide Application in the Colon
Phase 1B Study of KCC Peptide Application in the Colon
Status: Enrolling
Updated:  12/15/2016
University of Michigan
mi
from
Ann Arbor, MI
Study of KCC Peptide Application in the Colon
Phase 1B Study of KCC Peptide Application in the Colon
Status: Enrolling
Updated: 12/15/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Preventive Health Behavior in Women
Preventive Health Behavior in Women
Status: Enrolling
Updated:  12/15/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Preventive Health Behavior in Women
Preventive Health Behavior in Women
Status: Enrolling
Updated: 12/15/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer
Status: Enrolling
Updated:  12/19/2016
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer
Status: Enrolling
Updated: 12/19/2016
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver
Status: Enrolling
Updated:  1/10/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver
Status: Enrolling
Updated: 1/10/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)
Status: Enrolling
Updated:  1/10/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)
Status: Enrolling
Updated: 1/10/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New York, NY
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Research Site
mi
from
Parkville,
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Research Site
mi
from
Parkville,
Click here to add this to my saved trials
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated:  1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated: 1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Status: Enrolling
Updated:  1/25/2017
Arizona State University
mi
from
Phoenix, AZ
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Status: Enrolling
Updated: 1/25/2017
Arizona State University
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Endocytoscopy and Colorectal Neoplasia
The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia
Status: Enrolling
Updated:  1/25/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Endocytoscopy and Colorectal Neoplasia
The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia
Status: Enrolling
Updated: 1/25/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Northwest Alabama Cancer Center
mi
from
Florence, AL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Northwest Alabama Cancer Center
mi
from
Florence, AL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Highlands Oncology Group
mi
from
Bentonville, AR
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Highlands Oncology Group
mi
from
Bentonville, AR
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Pacific Medical Center
mi
from
Anaheim, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Pacific Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Kenmar Research Institute
mi
from
Los Angeles, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Kenmar Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
AMPM Research Clinic
mi
from
Miami Gardens, FL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
AMPM Research Clinic
mi
from
Miami Gardens, FL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Illinois Cancer Specialists
mi
from
Niles, IL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Illinois Cancer Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Indiana University Cancer Center
mi
from
Beech Grove, IN
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Indiana University Cancer Center
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
University of Louisville James Brown Cancer Center
mi
from
Louisville, KY
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
University of Louisville James Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Massachusetts General Hospital
mi
from
Boston, MA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Oncology Hematology West, PC dba Nebraska Cancer Specialists
mi
from
Omaha, NE
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Oncology Hematology West, PC dba Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Hematology and Oncology Associates of Central NY
mi
from
East Syracuse, NY
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Hematology and Oncology Associates of Central NY
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
New York Oncology, Hematology, P.C.
mi
from
Hudson, NY
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
New York Oncology, Hematology, P.C.
mi
from
Hudson, NY
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Toledo Community Oncology Program- Toledo Community Hospital
mi
from
Toledo, OH
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Toledo Community Oncology Program- Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Providence Portland Medical Center
mi
from
Portland, OR
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Cancer Centers of the Carolinas
mi
from
Spartanburg, SC
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Cancer Centers of the Carolinas
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
The Jones Clinic, PC
mi
from
Germantown, TN
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Tennessee Cancer Specialists
mi
from
Knoxville, TN
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Tennessee Cancer Specialists
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials